Oct. 26, 2021
阐明潜在临床试验的自然史
阐明潜在临床试验的自然史
A. 该图表传达了 NAPS2 研究为了解临床特征和生物标志物结果变化的努力，以便为未来的临床试验做好准备，从而延迟或预防显性路易体痴呆症（DLB）、帕金森病（PD）和多系统萎缩（MSA）。星号表示患快速眼动睡眠行为障碍（RBD）个体的典型神经功能（绿线）向神经功能进行性下降（红线）的表型转换。每个矩形代表一个综合评估，定期进行一系列临床和生物标志物测量。蓝线代表一种假设的生物标志物，在表型转换开始前数年开始变化。在前驱期，临床和生物标志物结果继续以相对线性和渐进式方式变化。B. 该图表传达了最终目标。如果生物标志物结果在前驱期持续变化，则可设计临床试验检验治疗（橙色箭头）是否会对一个或多个生物标志物（斜蓝线）产生积极影响，从而可能延迟或阻止表型转换为 DLB、PD 或 MSA。黑色箭头和延长的绿线表示典型神经功能延长。
Approximately 50% to 80% of people with isolated rapid eye movement (REM) sleep behavior disorder (RBD) will likely be diagnosed with an overt synucleinopathy within their lifetimes. Mayo Clinic is co-leading an international team of researchers working to identify biomarkers to predict that progression.
"Biomarkers can provide many insights since usually one or more are abnormal in individuals with RBD," says Bradley F. Boeve, M.D., a neurologist at Mayo Clinic in Rochester, Minnesota, and co-principal investigator of the study. "The trajectory of changes in those biomarkers will likely allow better predictions of which persons will develop an overt synucleinopathy, when the symptoms will develop and which specific disorder will evolve."
The international study — funded by an approximiately $35.1 million grant from the National Institutes of Health — aims to pave the way for clinical trials focused on stopping RBD from progressing to one of the overt synucleinopathies: dementia with Lewy bodies (DLB), Parkinson's disease (PD) or multiple system atrophy (MSA). The study's other lead researchers are from Washington University School of Medicine in St. Louis and The Neuro (Montreal Neurological Institute-Hospital) of McGill University.
The existing clinical and biomarker data on people with RBD is limited. Most of it comes from studies completed in single or a few centers over a short period of time.
"A comprehensive battery of measures and biomarkers from a multisite natural history study is critical," Dr. Boeve says. "Those measures and biomarkers could then be used to optimally design clinical trials to test whether any intervention is effective at delaying the onset or preventing the development of DLB, PD or MSA."
For more than two decades, Mayo Clinic has been at the forefront of research establishing the association of RBD with synucleinopathies. Not all individuals with a synucleinopathy have RBD. But the progression from isolated RBD to an overt neurodegenerative disease is well documented. The prodromal period can last from years to decades.
Participants in the international study will include members of the North American Prodromal Synucleinopathy (NAPS) Consortium, co-founded in 2018 by Dr. Boeve. Known as NAPS Stage 2 (NAPS2), the study will follow for five years approximately 430 participants with RBD and 60 people without sleep problems.
In a review published in the August 2021 issue of The Lancet Neurology, Dr. Boeve and colleagues from the International REM Sleep Behavior Disorder Study Group described 10 potential categories of biomarkers that have shown substantial promise.
Dr. Boeve notes that the greatest promise for predicting the evolution from RBD to an overt neurodegenerative disease will likely come from biomarkers that span multiple modalities.
"Some clinical findings or biomarkers — such as hyposmia and color discrimination problems — might appear early and change very slowly over time. Others — such as motor or cognitive impairment, or abnormalities on brain scans — might appear closer to phenoconversion," he says. "Ideally, we will find some combination of diagnostic biomarkers to identify the subtype of future synucleinopathy, prognostic biomarkers to inform proximity to phenoconversion and monitoring biomarkers to aid in tracking therapy response."
For more information
North American Prodromal Synucleinopathy (NAPS) Consortium.
Miglis MG, et al. Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. The Lancet Neurology. 2021;20:671.